Big pharma against CL move but WHO agrees


Right to get treatment: It was reported last year that there were 400,000 Hepatitis C sufferers in Malaysia, with only a fraction who could afford the RM300,000 cost. — AFP

KUALA LUMPUR: Malaysia’s bold move to impose compulsory licence (CL) on the drug sofosbuvir has been heavily criticised by big pharmaceutical companies, but has the support of the World Health Organisation (WHO).

WHO advocates universal health coverage and that means access to life-saving treatment, said its head of mission and representative to Malaysia, Brunei and Singapore Dr Lo Ying-Ru.

The Star Christmas Special Promo: Save 35% OFF Yearly. T&C applies.

Monthly Plan

RM 13.90/month

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Nation

Penang Hill funicular disruption due to power distribution issue, says PBBPP
Suspected explosives found on Nilai bomb maker at time of arrest
Floods: Situation in Terengganu improves
Six Orang Asli settlements in Kelantan identified as prone to natural disasters in monsoon season
No letters to EC from Perlis Speaker on vacancies yet, claims source
Perlis constitution allows by-elections if majority is affected, says former EC chair
Nilai bomb maker nabbed in Mantin
18-year-old loses nearly RM60,000 to prize scam syndicate
Dead man found trapped in culvert in Tapah
Man arrested for misusing another person’s MyKad to redeem Budi95

Others Also Read